Nat-Letrozole · DIN 02421585 · 2.5 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Letrozole · DIN 02421585
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2015-04-30
Health Canada: Marketed since 2015-02-03 · brand NAT-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421585)
Source record
DIN 02421585: Nat-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NAT
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421585
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90623
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: not checked (no credentials)